Impressive long-term response with pertuzumab and trastuzumab in HER2-positive breast cancer with brain metastasis

Michelangelo Russillo, Gianluigi Ferretti, Antonello Vidiri, Simona Gasparro, Francesco Cognetti, Domenica Pellegrini, Alessandra Fabi

Research output: Contribution to journalArticle


This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, developed a HER2 positive solitary brain metastasis in the left temporal lobe, without extracranial disease. She underwent surgery resection followed by stereotactic radiotherapy and, because of early brain progression, she was submitted to the first line therapy with pertuzumab, trastuzumab and weekly paclitaxel. After six months of treatment, a brain magnetic resonance imaging revealed a complete disappearance of brain recurrence, which persisted for more than 24 months.

Original languageEnglish
Pages (from-to)839-842
Number of pages4
JournalIn Vivo
Issue number4
Publication statusPublished - Jul 1 2018



  • Brain metastasis
  • Metastatic breast cancer
  • Pertuzumab

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this